Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.77 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.77 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.60 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 4/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27877728 | 1.00 | ITGB1 (0.77) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL2879404 | 1.00 | ITGB1 (0.77) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL2879401 | 1.00 | ITGB1 (0.77) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL23519426 | 0.94 | ITGB1 (0.75) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL23519443 | 0.94 | ITGB1 (0.75) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL23519669 | 0.94 | ITGB1 (0.75) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL23499866 | 0.94 | ITGB1 (0.75) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL23499865 | 0.94 | ITGB1 (0.75) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL7069740 | 0.93 | ALDH1A1 (0.70) | ITGB1ITGA5FKBP1AITGA4ITGA2 | |
| SCHEMBL7066469 | 0.93 | ALDH1A1 (0.70) | ITGB1ITGA5FKBP1AITGA4ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | claimed |
| JP-2002512625-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-8987306-B2 | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987306-B2 | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987306-B2 | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-03-24 | — | — | US | disclosed |
| CN-101006097-B | Vla-4 antagonists | MERCK SHARP & DOHME | 2012-07-11 | — | — | CN | disclosed |
| US-7776891-B2 | VLA-4 antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-15 | — | — | US | disclosed |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-15 | — | — | US | disclosed |
| US-20070219252-A1 | Vla-R Antagonists | MERCK SHARP & DOHME LLC | 2007-09-20 | — | — | US | disclosed |
| EP-1781686-A2 | VLA-4 ANTAGONISTS | Merck & Co., Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006023396-A2 | VLA-4 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6903075-B1 | Heterocyclic amide compounds as cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219252-A1 | Vla-R Antagonists | VCAM1, LTB4R, ITGA4 | ITGB1 15/4885ITGA5 16/4885FKBP1A 4398/4885 |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | ITGA2B, ITGA2, ITGB2 | ITGB1 4/4885ITGA5 9/4885FKBP1A 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.